Results 1 to 10 of about 226,492 (355)

Knowledge, attitudes, and practices of the United Arab Emirates population towards Herpes Zoster vaccination: A cross-sectional study

Human Vaccines & Immunotherapeutics, 2022
Herpes Zoster is a viral infection that occurs due to reactivation of the Varicella Zoster virus. A vaccine has been approved for adults aged 50 and above for the prevention of Herpes Zoster and its complications.
Teba Al-Khalidi, Radwa Genidy, Muna Almutawa, Mohammad Mustafa, Saryia Adra, Najem Edeen Kanawati, Thureya Binashour, Hiba Jawdat Barqawi   +7 more
doaj   +2 more sources

Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis

Frontiers in Pharmacology, 2023
Objective: Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy in treating immune-mediated inflammatory diseases (IMIDs). However, their safety profile in terms of herpes zoster infection remains unclear.
Qingling Xu, Liyuan He, Yufeng Yin
doaj   +2 more sources

Awareness and acceptability of herpes zoster vaccination in people living with HIV [PDF]

Preventive Medicine Reports
Objective: The recombinant herpes zoster vaccine is recommended for aging populations to prevent herpes zoster. We aimed to assess awareness of herpes zoster and acceptance of the herpes zoster vaccine acceptance among people living with HIV (PLWH ...
Christian Motet, Agnès Libois, Charlotte Martin, Nicolas Dauby   +3 more
doaj   +2 more sources

Herpes zoster in an immunocompetent adolescent – A case of rare occurrence [PDF]

Journal of Family Medicine and Primary Care
Herpes zoster is an acute viral infection caused by the reactivation of the varicella zoster virus. It occurs commonly in immunocompromised adults. Odontalgia may be an early prodromal symptom when herpes zoster involves the oral and maxillofacial region,
A.Winnifred Christy, T. J. R. Devathambi, R. Thanigainathan, M. Gobika Harini   +3 more
doaj   +2 more sources

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

New England Journal of Medicine, 2015
BACKGROUND In previous phase 1-2 clinical trials involving older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adjuvant system (called HZ/su) had a clinically acceptable safety profile and elicited a robust ...
Himal Lal, Anthony L Cunningham, Roman Chlibek   +2 more
exaly   +2 more sources

Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine

Human Vaccines & Immunotherapeutics, 2020
Herpes zoster (shingles) is a painful condition resulting from reactivation of latent varicella zoster virus (VZV). The Australian National Shingles Vaccination Program (commenced November 2016) provides free herpes zoster vaccination for eligible adults
John Litt, Robert Booy, Debra Bourke, Dominic E. Dwyer, Alan Leeb, Philip McCloud, Alicia N. Stein, Michael Woodward, Anthony L. Cunningham   +8 more
doaj   +2 more sources

Pioneer factors in viral infection

Frontiers in Immunology, 2023
Pioneer factors are transcription factors sharing the fascinating ability to bind to compact chromatin and thereby alter its transcriptional fate. Most pioneer factors are known for their importance during embryonic development, for instance, in inducing
Eva Neugebauer, Eva Neugebauer, Eva Neugebauer, Eva Neugebauer, Aura M. Bastidas-Quintero, Aura M. Bastidas-Quintero, Daniel Weidl, Florian Full, Florian Full, Florian Full   +9 more
doaj   +1 more source

Herpes zoster: A Review of Clinical Manifestations and Management

Viruses, 2022
The Varicella-zoster virus (VZV) or human herpes virus 3 is a neurotropic human alpha herpes virus responsible for chickenpox/varicella and shingles/Herpes zoster (HZ). This review will focus on HZ.
Anant D Patil, M. Goldust, U. Wollina
semanticscholar   +1 more source

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Open Forum Infectious Diseases, 2022
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high.
A. Strezova, J. Díez-Domingo, Kamal Al Shawafi, J. Tinoco, Meng Shi, P. Pirrotta, A. Mwakingwe-Omari, Michael Anitta Charles Eugene Jose-Fernando Piero Elisabet Adams Ahonen Andrews Athan BarbaGómez Barbanti Bar, M. Adams, Anitta Ahonen, C. Andrews, E. Athan, Jose-Fernando BarbaGómez, P. Barbanti, Elisabeth Barberan, A. Baty, N. Bengtsson, J. Berger-Roscher, Katarina Berndtsson Blom, J. Beytout, Loïc Boucher, C. Boutry, Alain Boye, François Brault, Laurie Breger, Carles Brotons Cuixart, Covadonga Caso, Christine Cerna, Huey‐Shinn Cheng, H. Cheong, E. Choo, C. Cunha, A. Cunningham, D. Curiac, Benoit Daguzan, Antje Dahmen, S. Datta, M. Desole, Emmanuel Di Paolo, M. Dionne, P. Dítě, J. Dutz, J. Earl, Tamara Eckermann, W. Ellison, J. Eremenko, Meral Esen, Takashi Eto, Xavier Farrés Fabré, C. Farrington, Murdo Ferguson, P. Ferrand, M. Finneran, David Francyk, Marsha Freedman, George Freeman, Antônio Tarcísio Freire, P. Gal, Jean-Sébastien Gauthier, B. Gerlach, W. Ghesquiere, I. Gorfinkel, Christine Grigat, J. Grosskopf, Monika Hamann, Pascal Hanrion, P. Hartley, Andrew Hastie, Ken Heaton, Agnes Himpel-Boenninghoff, T. Horácek, D. S. Hui, Yieng Huong, Shinn-Jang Hwang, G. Icardi, Gabriele Illies, J. Irimajiri, W. Jacob, A. Jambrecina, T. Avelino-Silva, G. Kalema, Hyo Youl Kim, C. Klein, U. Kleinecke, H. Koenig, Satu Kokko, P. Kosina, Susan V. Koski, Pekka Koskinen, Maximilian Kropp, Rie Kuroki, Outi Laajalahti, P. Lachance, Jacob Lee, Jin-Soo Lee, P. Levins, R. Lipetz, Bo Liu, Chiu-Shong Liu, Martin Lundvall, Luci Magimaiseelan, Mary Beth Manning, Jukka Markkula, Frederick H. Martin, Pyrene Martínez Piera, D. McNally, S. Mcneil, G. Migliorino, B. Moeckesch, Stephan Morscher, Michael Mueller, Abul Kashem Mohammad Munir, C. M. de Oliveira, Kenjiro Nakamura, Sílvia Narejos Pérez, Yuji Naritomi, P. Nault, José Luiz Neto, C. López, Hiroaki Ogata, Å. Olsson, P. Paavola, D. Park, Jan Patrick, K. Pauksens, Mercè Pérez Vera, L. Peltonen, Georg Plassmann, A. Põder, Terry L. Poling, Carol Pretswell, Samir Purnell-Mullick, George Raad, M. Redmond, Philippe Remaud, E. Riffer, Patrick Robert, Alex Rodríguez Badia, María Luisa Rodríguez de la Pinta, L. Rombo, R. Rosen, Shari Rozen, Dominique Saillard, B. Salaun, J. S. Berglund, J. Sauter, A. Schaefer, Isabelle Schenkenberger, Juergen Schmidt, Bernhard Schmitt, C. Schubert, A. Schuind, T. Schwarz, Ilkka Seppa, Edmund Kwok Yiu Sha, G. Shockey, Sylvia Shoffner, Elina Sirnela-Rif, T. Staniscia, H. Sueki, Shin-ichi Suzuki, D. Taminau, G. Tellier, Manuel Terns Riera, Azhar Toma, Nicole Toursarkissian, M. Turner, Benita Ukkonen, Anna Vilella Morató, Juergen Wachter, Brian Webster, Karl Wilhelm, Jonathan Wilson, Wilfred W Yeo, Chong-Jen Yu, T. Zahaf, I. Zahharova, C. Zerbini   +177 more
semanticscholar   +1 more source

Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics, 2022
Biologics and small molecules for inflammatory bowel disease (IBD) may increase infection risk. Herpes zoster causes acute and long‐term symptoms, but vaccination is not recommended in patients with IBD, unless >50 years of age.
S. Din, C. Selinger, C. Black, A. Ford
semanticscholar   +1 more source